+ 7.05
+ 2.21%
+ 4.00
+ 1.18%
+ 6.32
+ 1.54%
+ 1.27
+ 0.94%
+ 1.54
+ 0.9%

Analyzing The Price Action In GlaxoSmithKline Stock Today

April 15, 2021 10:43 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

GlaxoSmithKline's Stock Price And Volume Action

GlaxoSmithKline (NYSE:GSK) is currently up 5.41% to a price of $37.99. The stock's current volume for the day is 10.55 million, which is approximately 198.2% of its previous 30-day average volume of 5.32 million.

Why It's Moving

Benzinga Pro's real-time breaking news service shows some insight into what is affecting shares: GlaxoSmithKline shares are trading higher. The company announced it has taken the decision to stop enrolling patients in the phase II INDUCE-3 trial, including discontinuing treatment with feladilimab.

Insights On Recent Price Action

The moving average price of the stock over the past 50 days was $35.57 at the time this article was published. In the past fifty-two weeks, the stock price has been as high as $43.18 and as low as $33.26.

If you're looking for timely and concise explanations of why a stock is moving, check out Benzinga Pro. Subscribers get ‘Why Is It Moving' alerts as soon as our research team identifies the cause of the price action in a stock. Click here to learn more.


Movers Trading Ideas

Related Articles

BofA Says GlaxoSmithKline's Decision To Halt Feladilimab Studies Is Disappointing

GlaxoSmithKline plc (NYSE: GSK) announced the termination of the Phase II and Phase III studies of feladilimab, its ICOS receptor agonist in head and neck cancer. This comes as a disappointment, as the candidate could potentially address a multimillion-dollar market, according to BofA Securities. read more

Why AnPac Bio-Medical, Surface Oncology, CorMedix Are Rallying Today

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC), Surface Oncology, Inc. (NASDAQ: SURF) and CorMedix Inc. read more

Vir Biotech Expands Vaccine Collaboration With GlaxoSmithKline: What You Need to Know

Vir Biotechnology Inc (NASDAQ: VIR) shares were advancing Wednesday after the company announced an expansion of its coronavirus vaccine collaboration with GlaxoSmithKline plc (NYSE: GSK). read more

Why Dynavax Shares Are Rallying Today

Dynavax Technologies Corporation (NASDAQ: DVAX) shares are advancing solidly after the company and Clover Biopharma issued an update on their joint coronavirus vaccine program. read more